ICCMIcecure Medical Ltd
ICCM
Icecure Medical Ltd2,898
Mkt Cap
$46.71MVolume
113,318.0052W High
$1.6652W Low
$0.58PE Ratio
-2.66ICCM Fundamentals
Price
$0.6586Prev Close
$0.68Open
$0.65950D MA
$0.6813Beta
0.59Avg. Volume
406,154.05EPS (Annual)
-$0.2954P/B
5.04Rev/Employee
$45,708.33IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025...
PR Newswire·8d ago
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense Cryoablation for Low-Risk Breast Cancer
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense Cryoablation for Low-Risk Breast Cancer IceCure Expected to Report Record Fourth...
PR Newswire·1mo ago
IceCure's ProSense Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
IceCure's ProSense Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting IceCure's ProSense Cryoablation Featured in 4...
PR Newswire·1mo ago
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes IceCure Receives Notice of Patent Allowance in China for a Novel...
PR Newswire·2mo ago
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 PR Newswire...
PR Newswire·2mo ago
IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer IceCure's ProSense Cryoablation System Receives...
PR Newswire·2mo ago
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAESAREA, Israel, Nov. 14, 2025...
PR Newswire·2mo ago
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 PR...
PR Newswire·2mo ago
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased...
PR Newswire·2mo ago
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +6.35% and +3.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
<
1
2
...
>